Guillemin F, Berger L, Lapeyre M, Bellière-Calandry A
Département de radiothérapie, centre Jean-Perrin, 58, rue Montalembert, BP 5026, 63011 Clermont-Ferrand cedex 1, France.
Département de radiothérapie, centre Jean-Perrin, 58, rue Montalembert, BP 5026, 63011 Clermont-Ferrand cedex 1, France.
Cancer Radiother. 2021 Dec;25(8):747-754. doi: 10.1016/j.canrad.2021.03.001. Epub 2021 Jun 26.
Although three-dimensional conformal radiotherapy (3D-CRT) remains the gold standard as a curative treatment for NSCLC when surgery is not possible, intensity modulated radiotherapy (IMRT) is increasingly used routinely. The purpose of this study was to assess the clinical (immediate toxicities) and dosimetric impact of IMRT compared to 3D-CRT in the treatment of locally advanced (stages IIIA to IIIC) non-small cell lung cancer (NSCLC) treated with concomitant radiochemotherapy, while IMRT in lung cancer was implemented in the radiotherapy department of the Jean-Perrin Center.
Between March 2015 and October 2019, 64 patients treated with concomitant radiochemotherapy were retrospectively included. Thirty-two received 3D-CRT and 32 IMRT. The radiotherapy prescription was 66Gy in 33 fractions of 2Gy.
IMRT has improved coverage of target volumes (V95 increased by 14.81% in IMRT; P<0.001) without increasing doses to OARs and reducing dysphagia (RR=0.67; P=0.027). Low doses to the lung were not significantly increased in IMRT (pulmonary V5 increased by 7.46% in IMRT).
Intensity modulated radiotherapy, compared with the standard RC3D technique, improve the coverage of target volumes without increasing the dose to the OARs. It also improves the immediate tolerance of the treatment by reducing the number of dysphagia.
尽管三维适形放疗(3D-CRT)在无法进行手术时仍是非小细胞肺癌(NSCLC)根治性治疗的金标准,但调强放疗(IMRT)的常规应用越来越多。本研究的目的是评估在让·佩兰中心放疗科对局部晚期(IIIA至IIIC期)非小细胞肺癌(NSCLC)进行同步放化疗时,与3D-CRT相比,IMRT的临床(即时毒性)和剂量学影响。
回顾性纳入2015年3月至2019年10月期间接受同步放化疗的64例患者。32例接受3D-CRT,32例接受IMRT。放疗处方为66Gy,分33次,每次2Gy。
IMRT改善了靶区覆盖(IMRT中V95增加了14.81%;P<0.001),同时未增加对危及器官(OARs)的剂量,并减少了吞咽困难(RR=0.67;P=0.027)。IMRT中对肺的低剂量照射没有显著增加(IMRT中肺V5增加了7.46%)。
与标准的3D-CRT技术相比,调强放疗改善了靶区覆盖,而没有增加对OARs的剂量。它还通过减少吞咽困难的发生次数提高了治疗的即时耐受性。